Intracranial Efficacy of Next-Generation ALK-Targeted Therapies

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.

  1. All: Please discuss the efficacy of ALK inhibitors in brain metastases.
    1. REMARK study (Xiong A, et al. 2024. WCLC. OA09.03)
    2. CROWN trial (Solomon BJ, et al. Lancet Respir Med. 2023)
    3. ALTA-3 (Yang JC, et al. J Thorac Oncol. 2023)
    4. ALTA-1L/brigatinib (Camidge DR, et al. J Clin Oncol. 2021)
  2. Others

Related Content:

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management
Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations